The pharmacokinetics and pharmacodynamics of Procysteine in amyotrophic lateral sclerosis

Neurology

Volumn 52, Issue 7, 1999, Pages 1492-1494

  Cudkowicz, M E ^a,b   Sexton, P M ^b   Ellis, T ^b   Hayden, D L ^b   Gwilt, P E ^c   Whalen, J ^d   Brown Jr , R H ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d Transcend Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXO 4 THIAZOLIDINECARBOXYLIC ACID; GLUTATHIONE; 2-OXOTHIAZOLIDINE-4-CARBOXYLIC ACID; PYROGLUTAMIC ACID; THIAZOLE DERIVATIVE; THIAZOLIDINE DERIVATIVE;

ADULT; AGING; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BIOAVAILABILITY; CLINICAL ARTICLE; DRUG ACCUMULATION; DRUG EFFECT; DRUG SAFETY; FEMALE; HOMEOSTASIS; HUMAN; MALE; MUSCLE STRENGTH; ORAL DRUG ADMINISTRATION; PENETRANCE; PRIORITY JOURNAL; CEREBROSPINAL FLUID; CLINICAL TRIAL; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED;

ADMINISTRATION, ORAL; ADULT; AMYOTROPHIC LATERAL SCLEROSIS; GLUTATHIONE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; PYRROLIDONECARBOXYLIC ACID; THIAZOLES; THIAZOLIDINES;

EID: 0033594249     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.52.7.1492     Document Type: Article

References (10)

1. Williamson J, Boettcher B, Meister A. Intracellular cysteine delivery system that protects against toxicity by promoting glutathione synthesis. Proc Natl Acad Sci 1982;79:6246-6249.
2. Anderson M, Meister A. Marked increase of cysteine levels in many regions of the brains after administration of 2-oxothiazolidine-4-carboxylate. FASEB J 1989;3:1632-1636.
3. Munsat TL, Andres PL, Finison L, Conlon T, Thibodeau L. The natural history of motorneuron loss in ALS. Neurology 1988;38:452-458.
4. Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione. Anal Biochem 1968;27:502-522.
5. Beal SL, Sheiner LB. NONMEM Users' guide, part 1. Users' basic guide. Technical report. San Francisco: University of California Press, 1989.
6. Leaf CW, Whalen J. The pharmacokinetics and bioavailability of Procysteine in healthy male volunteers. Internal report. Cambridge, MA: Transcend Therapeutics, 1995.
7. Mesina JE, Page RH, Hetzel FW, Chopp M. Administration of L-2-oxothiazolidine-4-carboxylate increases glutathione levels in rat brain. Brain Res 1989;478:181-183.
8. Baghi M, Bagchi D, Patterson E, Tang L, Stohs S. Age-related changes in lipid peroxidation and antioxidant defense in Fischer 344 rats. Ann NY Acad Sci 1996;793:449-452.
9. Lang C, Naryshkin S, Schneider D, et al. Low blood glutathione in healthy aging adults. J Lab Clin Med 1992;120:720-725.
10. Louwerse ES, Weverling GJ, Bossuyt PMM, Meyjes FEP, de Jong V. Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch Neurol 1995; 52:559-564.